Therapeutic potential of highly diluted antibodies in antibiotic-resistant infection

Autor: Alexandra G. Emelianova, Natalia V. Petrova, Christophe Fremez, Maxime Fontanié, Sergey А. Tarasov, Оleg I. Epstein

Publikováno v: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 173

Klebsiella pneumoniae is one of the main causes of hospital-acquired infections. Its rate of antimicrobial resistance is rapidly increasing, while there are no licensed human vaccines against it. A novel therapeutic approach involves modulation of th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2125e56896bff8cd420986c63df1665d
https://pubmed.ncbi.nlm.nih.gov/35248735

Antiviral Activity of Ergoferon against Group A Rotavirus

Autor: O. I. Epshtein, I. P. Shilovskii, Musa Khaitov, A. G. Emelianova, M. S. Sundukova

Publikováno v: Bulletin of Experimental Biology and Medicine. 161:806-807

Antiviral activity of Ergoferon was studied in vitro on an experimental model of rotavirus infection in MA-104 cell line. In infected cells treated with Ergoferon, rotavirus titer was shown to decrease by 83 and 90% in comparison with cells treated w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec12115ad70e83575a8fc649012d303d
https://doi.org/10.1007/s10517-016-3516-x

Single Center Experience of Everolimus Combined with Long-Acting Octreotide in Patients (Pts) with Pretreated Advanced Well Differentiated Neuroendocrine Tumours (Nets) of Different Origin

Autor: A. Odintsova, Alla Markovich, G. Emelianova, Nadezhda Fedorovna Orel, A. Mnatsakanyan, Vera Gorbunova, A. Kuzminov

Publikováno v: Annals of Oncology. 25:iv401

Aim: To evaluate efficacy and safety of everolimus combined with long-acting octreotide in heavily pretreated patients with NETs. To determine predictive factors for everolimus efficacy. Methods: 33 pts with progressive well differentiated NETs (G1,G

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b9ea598eba03228016c3a0ef8584151e
https://doi.org/10.1093/annonc/mdu345.18

The Vegf Pathway in Patients with Pancreatic Neuroendocrine Tumors: Efficacy of Everolimus by Baseline Marker Level, and Prognostic and Predictive Effect Analyses from Radiant-3

Autor: L. Bengrine-Lefevre, J.L. Manzano, M. Cheung, R. Sharma, S. Dominguez-Tinajero, J. Valle, E.R. Braun, Y. Maeda, N. Reed, C. Bestani, V. Pesce, V. Alonso, M. Zappa, N. Pavlidis, S. Stergiopoulos, J.H. Turner, L. Anton-Aparicio, David Chen, S. Faivre, T. Shimoi, Manisha H. Shah, J.W. Valle, M. Bouattour, Richard C. Chao, G. De Velasco, Atilio Navarro, D.J. Pinato, P. Jimenez Fonseca, P. Escudero, J. Earl, T. Ito, O. Casanovas, Isabel Sevilla, Marianne Pavel, Clarisse Dromain, T.A. Walter, D. Mavroudis, A. Gorana, Chara Papadaki, M. Kudo, A. Carrato, T. Sasaki, R. García-Carbonero, C. Mateescu, E. Raymond, S. Lao-Sirieix, C. Metzer, Wendi Qian, J.E. Kurtz, G. Mendez, E. Sasaki, A. Markovich, Sandrine Kraemer, D. Petrakis, J. Alonso-Jara, Eleni Lagoudaki, P. García Alfonso, F. Marmissolle, F. Longo, I. Durán, J.M. Oconnor, G. Pentheroudakis, C. Dreyer, S. Belli, G. Armstrong, C. Lepère, P. Niccoli, V. Bruzgin, E. Grande, J. Capdevila, G. Cadiot, James C. Yao, Luis Ortega, E. Dominichini, V. Gorbounova, D. Smith, G. Lopez, E. Roca, Kjell Öberg, Ashok Panneerselvam, Shem Patyna, Tim Meyer, J. Craig, T. Shimoyama, P. Ruszniewski, A. Cabanne, R. Okamoto, David Cunningham, W. W. de Herder, A. Cervantes Ruiperez, L. Foster, Y. Omuro, V. Georgoulias, R. Hubner, Xin-Yun Huang, J.L. Raoul, J.J. Díez, Emmanuel Mitry, Simron Singh, S C Bowen Jones, Z. Mohamed, D. Horsch, Martyn Caplin, O. Hentic, Michel Ducreux, N. Orel, D. O'Toole, B. Chakrabarty, P. Hammel, A. Teulé, C. Law, V. Pachón, Ivan Borbath, W. Mansoor, Pippa Corrie, J.J. Reina, D. Castellano, Javier Sastre, J.C. Leyden, J. Souglakos, J. Fuster, P. Claringbold, Y-J. Bang, Eric Baudin, J. Seitz, R. Salazar, Bertram Wiedenmann, D. Tablot, G. Emelianova

Publikováno v: Annals of Oncology. 23:ix376

Background RADIANT-3 was a phase III study investigating the effect of the mammalian target of rapamycin inhibitor everolimus on progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumors (pNET; Yao et al, NEJM, 2011).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dfc20a6c93971e162035913106cc230b
https://doi.org/10.1093/annonc/mds405

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.